Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 9/20 | 0.69 |
| ▸ | ECE1 | P42892 | 1/20 | 0.68 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.68 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CTRC | Q99895 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497405 | 1.00 | GPR132 (0.69) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| SCHEMBL30037998 | 1.00 | GPR132 (0.69) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| SCHEMBL10659411 | 0.92 | GPR132 (0.72) | GPR132ECE1CMKLR2CMKLR1ACE | |
| SCHEMBL30037402 | 0.91 | GPR132 (0.61) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| SCHEMBL6860313 | 0.91 | GPR132 (0.61) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| SCHEMBL23489730 | 0.89 | ECE1 (0.65) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| SCHEMBL7415738 | 0.88 | ECE1 (0.64) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| SCHEMBL27520437 | 0.88 | ECE1 (0.64) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| Leucine SCHEMBL1406326 | 0.88 | GPR132 (0.56) | GPR132ECE1CMKLR2CMKLR1LMNA | |
| SCHEMBL6860349 | 0.87 | ECE1 (0.62) | GPR132ECE1CMKLR2CMKLR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240392273-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-3624846-B1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN | BHAMIS RES LABORATORY PVT LTD (IN) | 2024-08-07 | — | — | EP | disclosed |
| EP-4401758-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Takeda Pharmaceutical Company Limited (JP) | 2024-07-24 | — | — | EP | disclosed |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-11 | — | — | US | disclosed |
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2023-08-29 | — | — | US | disclosed |
| WO-2023042096-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | WO | disclosed |
| US-20200254094-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2020-08-13 | — | — | US | disclosed |
| US-10646569-B2 | High concentration protein formulations with reduced viscosity | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2020-05-12 | — | — | US | disclosed |
| EP-3624846-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2020-03-25 | — | — | EP | disclosed |
| US-20180333493-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2018-11-22 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| EP-2528898-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | Kareus Therapeutics SA (FR) | 2012-12-05 | — | — | EP | disclosed |
| CN-102712595-A | Novel compositions for reducing A beta 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTTICS SA | 2012-10-03 | — | — | CN | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
| CN-1043132-A | Dipeptidase derivant with enzyme inhibition | HOECHST AG (DE) | 1990-06-20 | — | — | CN | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646569-B2 | High concentration protein formulations with reduced viscosity | ALB, TTR, MAX | GPR132 4354/4885ECE1 2973/4885CMKLR2 2384/4885 |
| US-20200254094-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | GPR132 4354/4885ECE1 2973/4885CMKLR2 2384/4885 |
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | ALB, TTR, MAX | GPR132 4354/4885ECE1 2973/4885CMKLR2 2384/4885 |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | GPR132 4354/4885ECE1 2973/4885CMKLR2 2384/4885 |
| US-20180333493-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | GPR132 4354/4885ECE1 2973/4885CMKLR2 2384/4885 |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | GPR132 2559/4885ECE1 3655/4885CMKLR2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.